Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Eir
  6. /
  7. Zhejiang Tianyu Pharmaceutical Co., Ltd.
EIR
•Zhejiang Tianyu Pharmaceutical Co., Ltd.•March 4, 2022

Zhejiang Tianyu Pharmaceutical Co., Ltd. – FDA EIR, Mar 4, 2022

Record Details

An FDA inspection of Zhejiang Tianyu Pharmaceutical Co., Ltd., an intermediate and active pharmaceutical ingredient (API) manufacturer, was conducted from February 28 to March 4, 2022. This for-cause inspection, requested by the Center for Drug Evaluation and Research (CDER), followed Compliance Program 7356.00F and ICH Q7 guidelines, covering all six quality systems. The company's products intended for the US market are subject to the adulteration provisions of the Food, Drug, and Cosmetic (FD&C) Act.This inspection identified critical deficiencies, resulting in an "Official Action Indicated (OAI)" classification and a recommendation for a warning letter. Key issues included the firm's failure to extend investigations to other potentially affected batches following a failure or deviation. Furthermore, there was a lack of thorough review for unexplained discrepancies or components failing to meet specifications. Inadequate cleaning and maintenance of equipment and utensils also posed a risk of contamination, potentially impacting drug product safety, identity, strength, quality, or purity.These findings echo concerns from a previous OAI inspection in 2019, which cited issues such as insufficient investigation records, unclear contract laboratory responsibilities, deficient cleaning and process validation, and poor facility maintenance. The current inspection confirmed that the quality unit still has not adequately addressed potential impurities in the manufacturing process. The company is required to implement comprehensive corrective actions to resolve these persistent quality system failures and ensure compliance with regulatory standards.

Company
Zhejiang Tianyu Pharmaceutical Co., Ltd.
Inspection date
March 4, 2022
Product type
drugs
Office
Center for Drug Evaluation and Research
People
  • Rita Kabaso
  • Christopher D. Leach (Compliance Officer at FDA)
  • Erika V. Butler (Compliance Officer / Investigator)
  • Marcus A. Ray (Supervisory Consumer Safety Officer, China Office)
  • Yongjun Tu (recipient)
View Company Profile

ID · 0f12f5ed-7d07-4784-8a78-5a593bc53bc2

Other documents for Zhejiang Tianyu Pharmaceutical Co., Ltd.
  • 483 - 2024-11-29November 29, 2024
  • WARNING_LETTER - 2022-03-04March 4, 2022

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Zhejiang Tianyu Pharmaceutical Co., Ltd.
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.